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Anticoagulation therapy after mechanical heart
valve replacement is inevitable, due to the inherent
thrombogenicity of the mechanical valves (1,2).
Although the lifelong use of oral anticoagulation sig-
nificantly reduces the occurrence of thromboembolic
complications, it also causes bleeding risks and,
indeed, thromboembolic and bleeding complications
are the main causes of late mortality and morbidity in
patients with mechanical heart valve prostheses (3,4).
Thus, the adequate intensity of oral anticoagulation
may be defined as the level where both 
thromboembolic and bleeding complication rates are
the lowest (5).
Warfarin sodium (3-(α-acetonylbenzyl)-4-hydroxy-
coumarin) is a vitamin K antagonist that is the most
widely used oral anticoagulant drug for preventing
cardiovascular diseases after ischemic stroke and
thromboembolism related to atrial fibrillation (AF),
artificial heart valve replacement, deep-vein thrombo-
sis, and pulmonary embolism (6). However, because of
the large inter-individual variations in its dose 
requirements, warfarin requires continuous patient
monitoring and education in order to achieve desirable
outcomes (7). Currently, the International Normalized
Ratio (INR) of the prothrombin time is the most 
widely used measurement to determine the clotting
tendency of blood.
Thromboembolic hazards are related to not only the
type of mechanical valve implanted, but also to a 
variety of concomitant patient-related clinical factors,
such as AF (8). Since the introduction of prostheses
with improved designs (e.g., bileaflet mechanical
valves) during the late 1970s, it has been proposed that
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Background and aim of the study: The study aim was
to identify adequate therapeutic ranges of the
International Normalized Ratio (INR) in Korean
patients receiving warfarin after prosthetic mechani-
cal heart valve replacement.
Methods: Retrospective chart reviews were conduct-
ed of 818 patients for a total follow up period of 8,100
patient-years; all details of major complication
events of thromboembolism and bleeding were
recorded. The INR-incidence of complication curve
was plotted, and an adequate INR determined from
the intersections of 95% confidence interval (CI)
curves of complication rates to ensure the lowest
incidences of both thromboembolic and bleeding
complications. An analysis of a subgroup of patients
with atrial fibrillation (AF) was performed to evalu-
ate the complication occurrence.
Results: A total of 69 complications occurred, of
which 36 were thromboembolic events and 33 were
bleeding. The adequate ranges of INR were deter-
mined as: 2.0-2.5 for patients with aortic or mitral
valve replacement; 2.1-2.6 for those with aortic plus
mitral valve replacement; and 2.3-2.8 for those with
tricuspid valve replacement with or without other
valves. It has been shown that, by keeping the INR
levels within these therapeutic ranges, complication
risks could be significantly reduced by up to 51%.
The overall incidence of complications was increased
if the patients had AF (hazards risk (HR) = 1.27, 95%
CI = 1.05-1.52).
Conclusion: The study results may provide evidence
for the application of low-intensity warfarin thera-
pies in Asian patients, including Koreans. In addi-
tion, the method of determining adequate INR levels
by using INR-incidence of complications curves
might be employed in many clinical settings.
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a less-intensive oral anticoagulation therapy could
result in the successful prevention of bleeding 
complications, without any significant increase in
thromboembolic events (9-11). Moreover, especially in
Asian people, a lower intensity of anticoagulation is
recommended because of differences in race, in coagu-
lation characteristics, lifestyle (including diet), and
their vulnerability to thromboembolic diseases (12-16).
Although the effectiveness of low-intensity 
anticoagulation therapy in bileaflet mechanical valve
prostheses has been noted in several Korean studies
(17,18), there are as yet no specific guidelines for 
adequate therapeutic levels of anticoagulation in
Korean patients who have undergone bileaflet
mechanical heart valve replacement. An adequate
intensity of anticoagulation therapy is still widely 
disputed, and a less-intensive therapy is now carried
out empirically in many Korean hospitals, though
without a basis of any evidence (17-19).
Hence, the study aim was to identify adequate ther-
apeutic ranges of INR in Korean patients receiving
warfarin as anticoagulation therapy following
mechanical heart valve replacement.
Clinical material and methods
Patients and data collection
Retrospective chart reviews were conducted of a
total of 818 patients who had undergone prosthetic
mechanical heart valve replacements with St. Jude
Medical (SJM) mechanical valves at the Severance
Cardiovascular Hospital of Yonsei University Medical
Center between January 1984 and December 2008, and
had been followed up continuously at the outpatient
clinic of the hospital. All patients had received a single
brand of warfarin (Coumadin®) for their anticoagula-
tion therapy since the day of surgery, with a target INR
range of 1.8 to 3.0 by empirical evidence of the center;
1.8 to 2.5 for patients with aortic valve replacement
(AVR), and 2.0 to 3.0 for those with mitral valve
replacement (MVR), AVR plus MVR (double) 
replacement, and tricuspid valve replacement (TVR)
with or without other valves.
Anticoagulation complications
Anticoagulation-related complications were 
classified into thromboembolic events including valve
thrombosis and embolism and bleeding events 
according to the guidelines of Akins et al. (20).
Valve thrombosis referred to any thrombus not
caused by infection attached to or near an operated
valve that obstructed part of the blood flow path, 
interfered with valve function, or was sufficiently large
to warrant treatment. Embolism was any embolic
event that occurred without infection after the imme-
diate perioperative period. The manifestations of
embolism were neurologic events or non-cerebral
embolic events. Neurologic events included any 
central and new neurologic deficits that occurred after
the patient had emerged from anesthesia. Non-cere-
bral embolic events were an embolus documented
intraoperatively, at autopsy, or clinically that produced
signs or symptoms by complete or partial blockade of
a peripheral artery. A bleeding event was any episode
of major bleeding that caused hospitalization, perma-
nent injury or death, or necessitated transfusion (20).
INR assessments
The mean INR was calculated for the replaced valve
types as an independent predictor of thromboembolic
and bleeding events. In order to determine the 
incidences of thromboembolism and hemorrhage
according to INR levels, the measured INR values
were divided into five sections in order of their levels:
<1.75, 1.75-2.25, 2.25-2.75, 2.75-3.25, and >3.25. The
INR-incidence of complication curves were plotted
using the middle value of INR from the five sections
(1.5 and 3.5 in the case of <1.75 and >3.25, respective-
ly), and the adequate INR was determined from inter-
sections of 95% confidence interval (CI) curves of
complication rates to ensure the lowest incidences of
both thromboembolic and bleeding complications.
Adequate ranges were validated by comparing the
complication rates of INR within the ranges to those of
INR under or over the ranges.
All major complications were reviewed independ-
ently by a physician-investigator at the Yonsei
Cardiovascular Research Institute. The INR at the time
of an event was obtained from the hospital records; if
values had not been determined or were unavailable,
the last INR record was used. The electronic medical
records of patients were reviewed for complication his-
tories, INR measurements, and the clinical conditions
of patients, including any comorbidity of atrial 
fibrillation.
Approval to conduct the study was granted by the
Ethics Committee of the Yonsei University Medical
Center Institutional Review Board.
Statistical analysis
All data were analyzed using the Statistical Package
for Social Sciences Version 12.0 for Windows (SPSS
12.0K; SPSS Inc., Chicago, IL, USA). Complication
rates were expressed as linearized incidences per 100
patient-years (pt-yr). All data were expressed as the
mean ± SD, while 95% CIs for incidences were com-
puted based on the assumption of a Poisson distribu-
tion (21). A chi-square test was used for the detection
of statistically significant differences in complication
rates between groups. A p-value <0.05 was considered
to be statistically significant.
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Results
The  patient group included 348 males (43%) and 470
females (57%), with a mean age at surgery of 45 ± 13
years. Numbers of patients with AVR, MVR, AVR plus
MVR (double) valve, and TVR (with or without other
valves) were 179 (22%), 428 (52%), 181 (22%), and 30
(4%), respectively. The baseline characteristics of the
patients are listed in Table I.
The patients were followed until June 2009, after
their heart valve replacement. The follow up period
ranged from six to 252 months, and the total follow up
was 8,100 pt-yr. On average, patients were monitored
at intervals of 2.7 months. In total, the INR was 
measured 36,497 times, with an average of 45 ± 27
times per patient. A total of 41 deaths occurred during
the follow up period. Twenty of these deaths were
valve-related, but no fatality was caused by any com-
plications of anticoagulation therapy. The mean dura-
tion of follow up was 96 ± 71, 122 ± 68, 110 ± 70, and
98 ± 61 months for patients with AVR, MVR, AVR plus
MVR, and TVR with or without other valves, respec-
tively. Those patients who discontinued their regular
clinic visits for more than 12 months were considered
to be lost to follow up; hence, the completion rate of
total follow up was 94.5%.
A total of 69 complications occurred over the follow
up period (0.85% per pt-yr) (see Table II). Among these
were included 36 thromboembolic events (0.44% per
pt-yr), incorporating 28 cases of cerebral infarction
(0.35% per pt-yr). Bleeding complications occurred in
33 patients (0.41% per pt-yr), including 16 intracranial
bleedings (0.20% per pt-yr).
There were four thromboembolic and three bleeding
events among patients with AVR, with incidences of
0.28% and 0.21% per pt-yr, respectively.
Thromboembolic and bleeding events occurred in 22
patients (0.46% per pt-yr) and 17 patients (0.36% per
pt-yr) with MVR, in eight patients (0.48% per pt-yr)
and eight patients (0.48% per pt-yr) with AVR plus
MVR, and in two patients (0.78% per pt-yr) and five
patients (1.96% per pt-yr) with TVR with or without
other valves, respectively. The incidences of both
thromboembolic and bleeding events were lowest in
patients with AVR (Fig. 1).
The incidences of complications in each INR section
are shown in Figure 2. All four thromboembolic events
among patients with AVR were cerebral infarctions,
which occurred at INR levels below 2.25. Bleeding
events, including two cases of intracranial bleeding
and one case of gastrointestinal bleeding, occurred at
INR levels above 2.25. As the INR levels increased, the
thromboembolic rates decreased and bleeding rates
increased (Fig. 2A). The INR level at the point of 
intersection was 2.23, while those of the 95% CI curves
were 2.20 and 2.27.
Among patients with mitral valve prostheses there
were 17 cases of cerebral infarction, four of valve
thrombosis, and one case of mesenteric infarction.
Figure 1: Incidences of thromboembolic and bleeding events
in each valve position. †, Aortic plus mitral valve replace-
ment; ‡, tricuspid valve replacement with or without 
other valves.
Table I: Characteristics of the study patients (n = 818).
Characteristic Value
Age at surgery (years)* 45 ± 13
Gender (n)
Male 348 (43)
Female 470 (57)
Valve position (n)
Aortic 179 (22)
Mitral 428 (52)
Double† 181 (22)
Tricuspid‡ 30 (4)
*Mean ± SD.
Values in parentheses are percentages.
†, AVR plus MVR; ‡, TVR with or without other valves.
Table II: Characteristics of major complications.
Complications No. of Incidence
events (%/pt-yr)
Thromboembolism
Embolism
Cerebral infarction 28 0.35
Mesenteric infarction 1 0.02
Valve thrombosis 7 0.09
Total 36 0.44
Bleeding episodes
Intracranial bleeding 16 0.20
Gastrointestinal bleeding 7 0.09
Hematoma 6 0.07
Urogenital bleeding 3 0.04
Retroperitoneal bleeding 1 0.02
Total 33 0.41
Thromboembolism occurred when the INR levels were
below 1.75, except for four cases of cerebral infarction.
Bleeding events, including nine intracranial bleeds,
three urogenital bleeds, three hematomas, one 
gastrointestinal bleeding, and one retroperitoneal
bleeding, occurred at INR levels above 2.25. As depict-
ed in Figure 2B, the thromboembolic and bleeding
rates had opposite tendencies in relation to the INR
levels, and the complications crossed each other at an
INR level of 2.20; the points of intersection in the 95%
CI curves were 2.05 and 2.35.
The incidences of complications in patients with
double valve replacement included five cases of cere-
bral infarction and three of valve thrombosis. Bleeding
events occurred in eight cases, including three events
of intracranial bleeding, three of gastrointestinal 
bleeding, one hematoma, and one event of urogenital
bleeding. The incidences of complications had an
intersection at an INR level of 2.36, and those of the
95% CI curves were 2.32 and 2.40 (see Fig. 2C).
The two thromboembolic events identified among
patients with TVR with or without other valves were
cerebral infarctions, which occurred at INR levels
below 2.25. There were five bleeding events, with two
cases of intracranial bleeding, two of gastrointestinal
bleeding, and one hematoma. All hemorrhages
occurred when the INR levels were above 2.75. Only
one INR intersection of 2.50 was attained in both the
mean graph and 95% CI curves of thromboembolic
and bleeding complications (see Fig. 2D).
The adequate therapeutic ranges of INR for warfarin
therapy in Korean patients with SJM prosthetic heart
valve replacements were established on the basis of
target INR values, which were derived from the 
intersection of 95% CI curves of complication rates in
Figure 2. The adequate therapeutic ranges were 
determined to center the target INR values at a con-
fined distance of 0.5: 2.0-2.5 for AVR and MVR, 2.1-2.6
for AVR plus MVR, and 2.3-2.8 for TVR with or with-
out other valves.
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Figure 2: Incidences of thromboembolic and bleeding complications in patients with AVR (A), MVR (B), AVR plus MVR
(C), and TVR (D). The middle values of INR from the five sections (1.5 and 3.5 in the case of <1.75 and >3.25, respectively)
were used. -▲-, bleeding complications; -●-, thromboembolic complications; - - - - , 95% CI of bleeding complications; …….,
95% CI of thromboembolic complications.
The adequate ranges were validated by comparing
the complication rates of INR within the ranges to
those of INR under or over the ranges. Patients in the
‘within therapeutic’ group had statistically significant-
ly lower thromboembolic rates compared to those of
the ‘under therapeutic range’ group. Compared to the
‘over therapeutic range’ group, significantly lower
incidences of bleeding events were obtained in the
‘within therapeutic range’ group, except in patients
with AVR. The hazard ratios (HRs) of complications by
valve type are summarized in Table III. It was shown
that, by keeping INR levels within therapeutic ranges,
the complication risks could be significantly reduced
by up to 51% in patients with SJM heart valve 
prostheses.
In order to examine the influence of INR fluctuation
on complication occurrences in warfarin therapy, the
standard deviations of INR measurements in patients
with thromboembolic or bleeding complications were
compared to those in complication-free patients.
Patients with complications showed a greater
fluctuation of INR measurements than those without
complication histories, of which the mean of standard
deviations in INR was 0.92 ± 0.34 and 0.86 ± 0.64 in
patients with and without experiences of complica-
tions, respectively, despite the lack of statistical signif-
icance of the difference, with a p-value of 0.383.
The influence of AF on the complication occurrence
in patients with mechanical heart valve prostheses was
evaluated by comparing the incidences of thromboem-
bolic and bleeding events of patients with normal
sinus rhythm (NSR) and those of patients with AF 
(see Table IV). In total, 389 patients (48%) were found
to have AF, with 42 complication events occurring in
the AF subgroup (61% of the total complications). In
patients with double-valve replacement, increased
incidence rates in both complications were observed in
the AF subgroup. In patients with AVR and MVR, the
thromboembolic rates were increased in the AF sub-
group, whereas the bleeding rates decreased; the TVR
group showed an opposite tendency compared to
those with AVR and MVR. Overall, the complication
rates increased statistically significantly if patients had
AF (p = 0.007, HR = 1.26, 95% CI = 1.05-1.52), especial-
ly thromboembolism (p = 0.017, HR = 1.35, 95% 
CI = 1.02-1.77). However, the incidence of bleeding
events failed to show any statistically significant dif-
ference between the AF subgroup and the NSR group
(p = 0.126).
Discussion
The incidence of complications shows differences
among implanted valve positions as a result of 
structural differences inside the heart. Aortic valve
prostheses are known to have lower complication rates
compared to other prostheses. Indeed, in a long-term
multicenter follow up study with SJM mechanical
valve prostheses (22), the average incidences of throm-
boembolism were 0.53% per pt-yr for AVR, 1.64% per
pt-yr for MVR, and 0.79% per pt-yr for double-valve
replacement. Severe bleeding complication rates were
0.51%, 0.55%, and 1.31% per pt-yr, respectively. In a
previous long-term follow up study using SJM
mechanical valve prostheses (23), the incidences of
thromboembolism in AVR, MVR and double-valve
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Table III: Hazard ratios of complications in patients with prosthetic heart valve replacement.
Valve Desired Complication Outside TR* Within TR* HR§ 95% CI
position TR
Under Over Total
Aortic 2.0-2.5 All events 4 (0.73)# 2 (0.40) 6 (0.57) 1 (0.25)Ⅱ 0.72 0.62-0.83
Thromboembolism 4 (0.73)# 0 (0.00) 4 (0.38) 0 (0.00)Ⅱ 0.50 0.49-0.51
Bleeding 0 (0.00)# 2 (0.40) 2 (0.19) 1 (0.25)¶ 1.16 0.83-1.63
Mitral 2.0-2.5 All events 20 (1.23)# 17 (0.91)# 37 (1.06) 2 (0.16)Ⅱ 0.57 0.53-0.61
Thromboembolism 20 (1.23)# 1 (0.05) 21 (0.60) 1 (0.08)Ⅱ 0.57 0.52-0.62
Bleeding 0 (0.00)** 16 (0.85)# 16 (0.46) 1 (0.08)Ⅱ 0.59 0.52-0.66
Double† 2.1-2.6 All events 6 (0.97)# 8 (1.30)# 14 (1.13) 2 (0.48)Ⅱ 0.71 0.64-0.79
Thromboembolism 6 (0.97)# 1 (0.16) 7 (0.57) 1 (0.24)Ⅱ 0.71 0.62-0.82
Bleeding 0 (0.00)# 7 (1.14)# 7 (0.57) 1 (0.24)Ⅱ 0.71 0.62-0.82
Tricuspid‡ 2.3-2.8 All events 2 (1.69)# 5 (6.25)# 7 (3.53) 0 (0.00)Ⅱ 0.49 0.48-0.50
Thromboembolism 2 (1.69)# 0 (0.00) 2 (1.01) 0 (0.00)Ⅱ 0.50 0.49-0.50
Bleeding 0 (0.00) 5 (6.25)# 5 (2.52) 0 (0.00)Ⅱ 0.49 0.49-0.50
*No. of complications (incidence, % per pt-yr); †, Aortic plus mitral valve; ‡, Tricuspid valve replacement with or without other
valves; §, Hazard ratio of ‘within TR’ group, compared to ‘outside TR’ group; Ⅱp <0.0001 compared to ‘outside TR’ group; 
¶p = 0.365 compared to ‘outside TR’ group; #p <0.0001 compared to ‘within TR’ group; **p <0.05 compared to ‘within TR’ group.
CI: Confidence interval; HR: Hazards ratio; TR: Therapeutic range.
replacement were 0.33%, 0.54%, and 0.53% per pt-yr,
respectively. Typically, the bleeding rates were 0.25%,
0.35%, and 0.38% per pt-yr, respectively.
In the present study, the AVR group also showed the
lowest incidences in both complications, compared to
other valve replacement groups. On the other hand,
patients with TVR were found to have higher compli-
cation incidences than those with other valve 
replacements.
Because of the risk of complications, the anticoagula-
tion intensity should be controlled in an adequate
range, where the number of incidences of both throm-
boembolic and bleeding complications are the lowest.
Since the late 1970s, when bileaflet mechanical valves
were first introduced, it has been reported that blood
flow was more laminar and thromboembolic events
were considerably reduced (24,25). This brought about
a clinical apprehension regarding the bleeding risks
with previously recommended target INR levels.
However, studies suggesting less-intensive anticoagu-
lation levels have been continuously reported (9-11).
Although several studies have identified similar tar-
get INR values to those of the present study (26,27),
well-conducted and up-to-date guidelines on anticoag-
ulation levels after mechanical valve replacement have
recommended higher levels. Notably, the American
College of Chest Physicians (ACCP) 2004 Guideline (1)
recommends an INR of 2.5-3.5 for most patients with
mechanical prosthetic valves, and 2.0-3.0 for those
with bileaflet mechanical valves (e.g., the SJM device)
in the aortic position. The American Heart
Association/American College of Cardiology
(AHA/ACC) guidelines 2006 (28) suggest an INR of
2.0-3.0 for patients with mechanical aortic valves and
no risk factors (including AF), and 2.5-3.5 for the oth-
ers. The adequate therapeutic ranges of INR evaluated
in the present study were noticeably lower, though this
might be explained by ethnic differences, as the 
guidelines are based mainly on studies with
Caucasians. It is known that Asians are less vulnerable
to thrombotic diseases than Caucasians (29).
Studies of Asian populations have suggested consid-
erably lower intensities of warfarin therapy after
implanting mechanical valve prostheses. In a retro-
spective study of 214 Japanese patients with MVR, a
target INR range of 1.5-2.5 was reported to be safe for
both thromboembolic and bleeding complications (14).
In Chinese patients with CarboMedics valve implan-
tations (12), an INR range of 1.4-2.0 was concluded to
be optimum, while a retrospective study with 805
Chinese patients receiving SJM valves reported lower
incidences of thromboembolism and bleeding, with an
INR between 2.0 and 2.5 (13), which was exactly the
same as found in the AVR and MVR groups of the
present study.
The mean age at surgery in the present study was 45
± 13.3 years, which was less than that reported else-
where by Butchart et al. (30) (ca. 65 years) and Toole et
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Table IV: Comparisons of thromboembolic and hemorrhagic complications in patients with and without atrial fibrillation (AF).*
Valve position Parameter NSR AF p-value
Aortic No. of patients 162 17
Complication events 6 (0.48) 1 (0.51) 0.763
Thromboembolism 3 (0.24) 1 (0.51) 0.002
Bleeding 3 (0.24) 0 (0.00) <0.0001
Mitral No. of patients 164 264
Complication events 16 (0.84) 21 (0.74) 0.425
Thromboembolism 6 (0.31) 14 (0.49) 0.044
Bleeding 10 (0.52) 7 (0.25) 0.002
Double† No. of patients 93 88
Complication events 4 (0.51) 13 (1.50) <0.0001
Thromboembolism 3 (0.38) 5 (0.58) 0.041
Bleeding 1 (0.13) 8 (0.93) <0.0001
Tricuspid‡ No. of patients 10 20
Complication events 1 (1.66) 7 (3.59) <0.0001
Thromboembolism 1 (1.66) 2 (1.03) 0.0001
Bleeding 0 (0.00) 5 (2.57) <0.0001
Total No. of patients 429 389
Complication events 27 (0.67) 42 (1.02) 0.007
Thromboembolism 13 (0.32) 22 (0.54) 0.017
Bleeding 14 (0.35) 20 (0.49) 0.126
*Variables are given as number (incidence, % per pt-yr); †, AVR plus MVR; ‡, TVR with or without other valves.
NSR: Normal sinus rhythm.
al. (31) (ca. 55 years). Thus, the results of the present
study cannot be compared directly to those of other
studies with older patients. A recent study compared
the complication rates between patients with a low
INR target (1.5-2.5) and a conventional INR target 
2.0-3.0); in this case, the patients were of a similar age
(50 years) to those in the present study. The study
results revealed that a low INR target was safe and
practical in low-risk patients after bileaflet mechanical
AVR. Although the thrombotic event rates were similar
in the two groups, a significant reduction in bleeding
events was apparent in the low-INR group (32).
Fluctuation in the INR is known to be a risk factor for
complications in warfarin therapy (33). In the present
study, however, there was no significant influence of
INR fluctuation on complication rates in warfarin ther-
apy, although patients with complications showed a
greater fluctuation of INR.
Atrial fibrillation is not only the most common signifi-
cant cardiac rhythm disorder, but also an important
independent risk factor for ischemic stroke. The 
influence of AF on thrombotic events is well known,
and in the present study those patients with a comor-
bidity of AF were found to have a greater risk of
thromboembolism, which was consistent with prior
findings (34,35).
Study limitations
The main limitation of the study was the small num-
ber of collected INR values per patient, which could
have resulted in a large variability of follow up among
patients. The failure to have sufficient statistical power
due to extremely low complication rates might repre-
sent an additional limitation of the study.
In conclusion, this is the first long-term follow up study
of a large population to investigate adequate anticoag-
ulation levels in Korean patients with SJM mechanical
heart valve prostheses. The adequate INR values were
as follows: 2.0-2.5 for patients with AVR or MVR, 
2.1-2.6 for those with AVR plus MVR, and 2.3-2.8 for
those with TVR with or without other valves. The
results of the study can be considered as evidence for
the application of low-intensity warfarin therapies in
Asian patients, including Koreans. Moreover, it is
expected that the method used to determine optimal
INR levels, via the INR-incidence of complications
curves, could be utilized in many clinical settings.
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